Article info
PDFNew targets II
Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases
- Correspondence to:
T Hünig
Institute for Virology and Immunobiology, University of Würzburg, Versbacherstr. 7, 97078 Würzburg, Germany; huenigvim.uni-wuerzburg.de
Citation
Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases
Publication history
- First published October 20, 2005.
Online issue publication
April 13, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2005 by Annals of the Rheumatic Diseases